Cardiogenic shock: a review of contemporary approaches and ongoing challenges

Lea R Goren1, Xuan Ding1, Maeve Jones-O'Connor1

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Future Cardiology
|August 30, 2025
PubMed

Insights

Cardiogenic shock (CS) management is complex. This review covers CS definition, pathophysiology, and evidence-based treatments like revascularization and microaxial flow pumps, highlighting knowledge gaps and ongoing trials.

Area of Science:

  • Cardiology
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) is a critical condition of inadequate cardiac output leading to organ failure.
  • Understanding CS heterogeneity and classification is crucial for effective management.

Purpose of the Study:

  • To review the definition, pathophysiology, classification, and management of cardiogenic shock.
  • To highlight recent advances and evidence-based therapeutic approaches for CS.
  • To identify current evidence gaps and ongoing trials in CS management.

Main Methods:

  • Literature review focusing on cardiogenic shock.
  • Analysis of recent advances in CS phenotypic heterogeneity and classification.
  • Evaluation of evidence-based therapeutic interventions and mechanical circulatory support (MCS) devices.

Main Results:

  • Emergent revascularization and microaxial flow pumps show survival benefits in specific CS cases (e.g., STEMI).
  • Evidence for other medical therapies and MCS devices in CS remains limited.
  • Significant gaps in evidence exist, with ongoing trials poised to inform future clinical practice.

Conclusions:

  • Effective cardiogenic shock management requires understanding its complex pathophysiology and heterogeneity.
  • Evidence-based treatments, while limited, offer survival benefits in select CS populations.
  • Further research and ongoing clinical trials are essential to refine CS treatment strategies.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
998
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K